Alterations of bone metabolism of patients with primary and platinum-sensitive recurrent tuboovarian carcinoma induced by platinum-based chemotherapy with and without bevacizumab

Abstract

Objective: During the last two decades, survival rates of patients with tuboovarian carcinoma (TOC) have markedly improved, now highlighting the importance of late sequelae of antineoplastic treatment. Direct effects of chemotherapy on the bone metabolism of TOC patients are only poorly elucidated so far. The present translational project sought to gain detailed information on the influence of platinum-based chemotherapy with or without bevacizumab (Bev) on the expression of various bone markers in patients with primary or platinum-sensitive recurrent TOC.